Kymera Therapeutics (NASDAQ:KYMR) Hits New 52-Week High on Analyst Upgrade
Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Free Report) hit a new 52-week high on Tuesday after Barclays raised their price target on the stock from $139.00 to $170.00. Barclays currently has an overweight rating on the stock. Kymera Therapeutics traded as high as $133.88 and last traded at $132.5350, with a volume of […]
3 Nov 15:21 · The Markets Daily